Close

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

February 12, 2013 7:08 AM EST Send to a Friend
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login